# EDGAR Filing Document

**Accession Number:** 0000855683
**File Stem:** 0001437749-25-024900
**Filing Date:** 2025-8
**Character Count:** 13163
**Document Hash:** 6f31b0960e34a231e8d79269634dc09c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-024900.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001437749-25-024900

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250731

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MILESTONE SCIENTIFIC INC.
- **CENTRAL INDEX KEY:** 0000855683
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133545623
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14053
- **FILM NUMBER:** 251186183

**BUSINESS ADDRESS:**
- **STREET 1:** 220 SOUTH ORANGE AVENUE
- **CITY:** LIVINGSTON
- **STATE:** NJ
- **ZIP:** 07039
- **BUSINESS PHONE:** (973) 535-2717

**MAIL ADDRESS:**
- **STREET 1:** 220 SOUTH ORANGE AVENUE
- **CITY:** LIVINGSTON
- **STATE:** NJ
- **ZIP:** 07039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MILESTONE SCIENTIFIC INC/NJ
- **DATE OF NAME CHANGE:** 19970409

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** U S OPPORTUNITY SEARCH INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? mlss20250804_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

 **Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 31, 2025**

## Milestone Scientific Inc.
(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction<br> of incorporation) | **001-14053**<br> (Commission<br> File Number) | **13-3545623**<br> (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **425 Eagle Rock Avenue** <br> **Suite 403** <br> **Roseland, New Jersey**<br> (Address of principal executive offices) | **07068**<br> (Zip Code) |

---

Registrant's telephone number, including area code **(973) 535-2717**

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name on exchange on which registered |
| Common Stock | MLSS | NYSE American |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

------

**Item 5.02** — **Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers**

Effective July 31, 2025, the Board of Directors of Milestone Scientific Inc. (the "**Company**") appointed Eric Hines as President and Chief Executive Officer, and as a director of the Company. From July 31, 2025 through December 31, 2025 (the "**Initial Term**"), Mr. Hines will be entitled to base compensation at the rate of $15,000 per month. From January 1, 2026, subject to Mr. Hines's continued employment at the Company by mutual agreement (the "**Extended Term**"), Mr. Hines will be entitled to base compensation at the rate of $25,000 per month. In addition to his base compensation, Mr. Hines will be granted options (the "**Signing Bonus Options**") for an aggregate of 2,000,000 shares of Common Stock of the Company. The exercise price of the Signing Bonus Options will be the fair market value of shares of Common Stock of the Company on the date of grant. Ten percent (10%) of the Signing Bonus Options will vest on the date of grant and the remaining ninety percent (90%) will vest in three (3) equal annual installments of 600,000 shares each. In addition, it is expected that Mr. Hines would be entitled to receive an annual incentive bonus, comprised of (i) separate performance-based bonuses; and (ii) a discretionary bonus, each as determined by the Company's Compensation Committee, in its sole discretion.

Mr. Hines most recently served as President of North America at Ex Libris Group (September 2014 - June 2021), a global provider of cloud-based solutions for higher education and libraries. From June 2021 to July 2025, Mr. Hines was involved in providing consulting services for Alethea, a technology start-up company, and also invested in commercial and personal real estate ventures. Prior to his role at Ex Libris Group, Mr. Hines held various roles at NICE Systems (October 2004-June 2014), a multinational company that designs and manufactures smart home security and automation products. Mr. Hines served as Senior Director of Sales at NICE Systems from October 2004 to November 2005, and subsequently served as Vice President of several North American divisions of NICE Systems from November 2005 through June 2014. Prior thereto, Mr. Hines served as Regional Director of Sales at AMDOCS Clarify CRM (October 2003- October 2004), a provider of customer relationship management (CRM) solutions to the communications industry.

Mr. Hines received a BS in Chemistry from Wake Forest University in 1989 and an MBA in International Business from Xavier University in 1996.

**Item 8.01 - Other Events**

On August 1, 2025, the Company issued a press release announcing the appointment of Mr. Hines as Chief Executive Officer. The press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

99.1 [Press Release August 1, 2025](ex_848438.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MILESTONE SCIENTIFIC INC.** | **MILESTONE SCIENTIFIC INC.** |
| Dated: August 5, 2025  | By:  | /s/ Neal Goldman |
|  |  | Neal Goldman  |
|  |  | Interim Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![m01.jpg](m01.jpg)

**Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer**

*Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone*'*s next phase of commercial execution*

**Roseland, NJ, August 1, 2025** – **Milestone Scientific Inc. (NYSE: MLSS)**, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately.

Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 million to over $100 million. At Ex Libris, he launched multiple new product lines; managed marketing, sales, and service organizations; and drove new customer expansion. Earlier in his career, Mr. Hines held executive positions at NICE Systems, where he led an over $90 million North American security business, and previously served in the Customer Experience Management (CEM) division, where he oversaw both the central and west regions, as well as channel sales and customer experience management. Across his career, Mr. Hines has consistently built high-performance teams, delivered top-line growth, and led commercial expansions into new geographies and industry verticals. He holds a BA in Chemistry from Wake Forest University and an MBA in International Business from Xavier University.

Neal Goldman, Chairman of the Board of Milestone Scientific, commented, "We are pleased to welcome Eric as CEO. His leadership experience growing complex, commercially disciplined organizations will be critical as we work to accelerate the adoption of our CompuFlo® technology. We have made meaningful progress on the reimbursement front, including the assignment of Medicare Part B payment rates under CPT® code 0777T across multiple jurisdictions, as well as initial commercial insurance payments. We believe Eric is the right executive to build on this foundation, expand our presence in the medical and dental markets, and guide the Company as we pursue new clinical indications and global opportunities."

Eric C. Hines, Chief Executive Officer of Milestone Scientific, stated, "I am honored to lead Milestone Scientific at such a pivotal moment for the Company. During my diligence, I was impressed by the strength of the CompuFlo® platform, the clinical validation supporting its use, and the Company's recent reimbursement achievements, including favorable Medicare payment rates. These milestones create a strong base for expanded commercial adoption. I also see compelling opportunities in the dental segment, where Milestone's STA® system remains highly differentiated, and in extending the CompuFlo® technology into new indications and international markets. Having worked closely with customers across a range of industries, including healthcare, I appreciate the importance of technologies that deliver both clinical and economic value. I look forward to working with the team to execute on these priorities and deliver long-term value for our stakeholders."

------

**About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient, and increase the overall patient comfort and safety. The Company leverages its proprietary DPS Dynamic Pressure Sensing Technology® platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetics. To learn more, view the <u>MLSS brand video</u> or visit <u>milestonescientific.com</u>.

***Safe Harbor Statement***

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.* 

**Contact:** 

Crescendo Communications, LLC

Email: <u>mlss@crescendo-ir.com</u>

Tel: 212-671-1020